BR0106680A - Liberação transdermal de lasofoxifeno - Google Patents

Liberação transdermal de lasofoxifeno

Info

Publication number
BR0106680A
BR0106680A BR0106680-3A BR0106680A BR0106680A BR 0106680 A BR0106680 A BR 0106680A BR 0106680 A BR0106680 A BR 0106680A BR 0106680 A BR0106680 A BR 0106680A
Authority
BR
Brazil
Prior art keywords
devices
lasofoxifene
transdermal
reservoir
drug
Prior art date
Application number
BR0106680-3A
Other languages
English (en)
Portuguese (pt)
Inventor
David Fikstad
Danyi Quan
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of BR0106680A publication Critical patent/BR0106680A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0106680-3A 2000-06-01 2001-05-31 Liberação transdermal de lasofoxifeno BR0106680A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20878900P 2000-06-01 2000-06-01
PCT/US2001/017567 WO2001091724A2 (en) 2000-06-01 2001-05-31 Transdermal delivery of lasofoxifene

Publications (1)

Publication Number Publication Date
BR0106680A true BR0106680A (pt) 2002-04-30

Family

ID=22776068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0106680-3A BR0106680A (pt) 2000-06-01 2001-05-31 Liberação transdermal de lasofoxifeno

Country Status (24)

Country Link
US (1) US20020037311A1 (cg-RX-API-DMAC7.html)
EP (1) EP1229909B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003534368A (cg-RX-API-DMAC7.html)
KR (1) KR100795870B1 (cg-RX-API-DMAC7.html)
CN (1) CN1400897A (cg-RX-API-DMAC7.html)
AT (1) ATE253910T1 (cg-RX-API-DMAC7.html)
AU (2) AU785199B2 (cg-RX-API-DMAC7.html)
BR (1) BR0106680A (cg-RX-API-DMAC7.html)
CA (1) CA2380769A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2002488A3 (cg-RX-API-DMAC7.html)
DE (1) DE60101206T2 (cg-RX-API-DMAC7.html)
DK (1) DK1229909T3 (cg-RX-API-DMAC7.html)
ES (1) ES2210168T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052472A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202592A3 (cg-RX-API-DMAC7.html)
IL (2) IL147640A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02001152A (cg-RX-API-DMAC7.html)
NZ (1) NZ516582A (cg-RX-API-DMAC7.html)
PL (1) PL201222B1 (cg-RX-API-DMAC7.html)
PT (1) PT1229909E (cg-RX-API-DMAC7.html)
RU (1) RU2328276C2 (cg-RX-API-DMAC7.html)
TR (1) TR200400241T4 (cg-RX-API-DMAC7.html)
WO (1) WO2001091724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200519B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7564908B2 (en) * 2004-09-23 2009-07-21 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
US7804912B2 (en) * 2004-09-23 2010-09-28 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
EP2167001A4 (en) * 2007-07-10 2012-10-31 Agile Therapeutics Inc DEVICE FOR THE DERIVED ULTRASONIC WELDING
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
CN103751138A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN103830207A (zh) * 2014-03-14 2014-06-04 崔书豪 一种酒石酸拉索昔芬贴膏剂
KR20180035209A (ko) * 2015-07-24 2018-04-05 킴벌리-클라크 월드와이드, 인크. 종양에 대한 활성제의 더 나은 전달 방법
US10737082B2 (en) * 2015-07-24 2020-08-11 Sorrento Therapeutics, Inc. Methods for lymphatic delivery of active agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
CA2208132A1 (en) * 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Also Published As

Publication number Publication date
CZ2002488A3 (cs) 2002-06-12
RU2002105378A (ru) 2003-11-10
US20020037311A1 (en) 2002-03-28
IL147640A (en) 2007-03-08
PT1229909E (pt) 2004-04-30
PL201222B1 (pl) 2009-03-31
NZ516582A (en) 2004-08-27
PL354628A1 (en) 2004-02-09
IL147640A0 (en) 2002-08-14
WO2001091724A3 (en) 2002-05-30
DE60101206D1 (de) 2003-12-18
DE60101206T2 (de) 2004-09-02
ATE253910T1 (de) 2003-11-15
AU6523501A (en) 2001-12-11
KR100795870B1 (ko) 2008-01-21
MXPA02001152A (es) 2002-08-20
HK1052472A1 (zh) 2003-09-19
EP1229909B1 (en) 2003-11-12
HUP0202592A2 (hu) 2002-12-28
TR200400241T4 (tr) 2004-04-21
HUP0202592A3 (en) 2003-07-28
AU2007200426A1 (en) 2007-02-22
JP2003534368A (ja) 2003-11-18
WO2001091724A2 (en) 2001-12-06
KR20030025219A (ko) 2003-03-28
RU2328276C2 (ru) 2008-07-10
ZA200200519B (en) 2003-04-22
CN1400897A (zh) 2003-03-05
AU785199B2 (en) 2006-11-02
CA2380769A1 (en) 2001-12-06
EP1229909A2 (en) 2002-08-14
DK1229909T3 (da) 2004-03-15
ES2210168T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ES2245649T3 (es) Un sistema de entrega de farmaco dual adhesivo transdermico.
ES2924899T3 (es) Sistema de administración transdérmica que contiene rotigotina
ES2954087T3 (es) Sistema de administración transdérmica que incluye un mediador de interfase
BR9712806A (pt) Emplastro de matriz adesiva sensìvel à pressão para liberação transdérmica de sais de agentes farmacêuticos
DE602005011653D1 (de) Medizinprodukt mit gewebeabhängiger arzneimittelelution
TW200514590A (en) Hydrophilic adhesives for delivery of herbal medicines
CN104582693A (zh) 多层药物递送系统
US8940326B2 (en) Transdermal patch and method for delivery of vitamin B12
PT1229909E (pt) Entrega transdermica de lasofoxifeno
JP4430120B2 (ja) 抗真菌症用貼付剤
US11583505B2 (en) Over-patch having improved compatibility and a long adhesion duration and method for producing said over-patch
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
NZ332746A (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
EP2872126B1 (en) Pharmaceutical patch for transdermal administration of tapentadol
CA2480683A1 (en) Assembled unit consisting of individually separable transdermal therapeutic systems
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
CN100450480C (zh) 水凝胶型甲巯咪唑贴剂
CN101612141B (zh) 丁丙诺啡贴剂
AU2016322440B2 (en) Medical plaster
KR102844541B1 (ko) 로티고틴 함유 첩부제
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
BRPI0412010A (pt) sistema de distribuição de drogas tópicas
MY129063A (en) Transdermal delivery of lasofoxifene

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/00

Ipc: A61K 31/40 (2010.01), A61K 9/70 (2010.01), A61P 3/

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.